Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Infographics
-
Expand to See More
PASO DOBLE Infographic
5-Years of Dovato Infographic
EACS 2023 SOUND Infographic
IAS 2023 D2ARLING Poster
IAS 2023 Efficacy Infographic
AIDS 2022 Ageing Infographic
Croi 2023 Rumba Infographic
AIDS 2022 RWE Infographic
Positive Perspectives Infographic
GEMINI 144-Week Adherence Infographic
TANGO 144-Week Data Infographic
SALSA 48-Week Update Infographic
STAT 48-Week Infographic
Patient Resources
-
Expand to See More
Dovato Post Prescription Tear Off Pad - Switch Patient
A tear off leaflet to be given to a PLHIV who has been switched to Dovato from another treatment option.
Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Switch Patients
A tear off leaflet in Brazilian Portuguese to be given a PLHIV who has been switched to Dovato from another treatment option.
Dovato Post Prescription Tear Off Pad - Naïve Patient
A tear off leaflet to be given to a PLHIV who has been initiated on Dovato following a new diagnosis.
Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Naive Patient
A tear off leaflet in Brazilian Portuguese to be given to a PLHIV who has been initiated on Dovato following a new diagnosis.
Dovato Post Prescription Patient Information Booklet
A printed A6 booklet to provide practical information for patients post-prescription of Dovato.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: July 2024 | PM-IE-DLL-WCNT-200024
